Allogene Therapeutics (ALLO)
Nasdaq Market Open
Allogene Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic, or donor-derived, T cell therapies for cancer and autoimmune disease. Its work sits within the broader field of cell therapy, where immune cells are engineered to recognise and attack disease-related targets. Unlike autologous therapies, which are manufactured from each individual patient’s own cells, Allogene’s approach is intended to create “off-the-shelf” products that can be produced in advance and made available when needed.
The company’s candidates are genetically modified T cells designed to target malignant cells in oncology or eliminate harmful immune cells in autoimmune disorders. Its core development areas include large B-cell lymphoma, autoimmune disease and renal cell carcinoma. These programmes reflect the company’s focus on diseases where existing treatments may be insufficient, difficult to access or associated with relapse.
Allogene’s platform aims to address some of the practical challenges of personalised cell therapy, including manufacturing time, variability between patient-derived products and the need for rapid treatment in aggressive diseases. Donor-based cell therapy also brings scientific and clinical challenges, including persistence, immune compatibility and safety, which the company seeks to manage through cell engineering and clinical development.
As a clinical-stage company, Allogene does not resemble a mature pharmaceutical business with a broad commercial portfolio. Its value is closely linked to the progress of its pipeline, trial outcomes, regulatory interactions and the broader competitive landscape for engineered immune-cell therapies.
Last updated
- Market Cap
- 690.31M
- P/E
- —
- P/FCF
- —
- P/S
- —
- Enterprise Value
- 660M
- Sector
- Health Care
- Industry
- Biological Products, Except Diagnostic Substances
- Address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
U.S. CAR T-Cell Therapies Market Grows at 30.4% CAGR, Soars USD 42.61 Billion by 2035
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
Allogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound?
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
CollPlant Biotechnologies (CLGN) Soars 8.2%: Is Further Upside Left in the Stock?
Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
Omega Therapeutics, Inc. (OMGA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
How Allogene (ALLO) Stock Stands Out in a Strong Industry
Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 690.31M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 660M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 2.48
- P/S
P/S ratio compares a company's share price to its revenue per share.
- —
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -3.76
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- —
- EPS
- -0.5
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -109.53M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -62.31%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -43.88%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 9.65
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 9.65
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 1.07
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 6.88M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 2
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -46.09M | -42.4M | -44.9M | -56.82M | -65.19M |
| EBITDA | -43.22M | -39.35M | -41.8M | -51.33M | -62.09M |
| Net income | -42.61M | -38.81M | -41.4M | -50.94M | -59.73M |
| Basic EPS | -0.18 | -0.17 | -0.19 | -0.23 | -0.28 |
| Diluted EPS | -0.18 | -0.17 | -0.19 | -0.23 | -0.28 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 395.96M | 415.91M | 439.77M | 470.59M | 507.98M |
| Total liabilities | 117.08M | 123.36M | 124.44M | 126.03M | 122.59M |
| Total equity | 278.88M | 292.54M | 315.33M | 344.56M | 385.39M |
| Cash & equivalents | 30.31M | 51.69M | 37.82M | 52.33M | 42.46M |
| Current assets | 273.29M | 257.75M | 260.72M | 282.66M | 291.58M |
| Current liabilities | 28.33M | 32.51M | 31.83M | 31.68M | 30.02M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -12.91M | -27.6M | -29.69M | -39.03M | -52.93M |
| Investing cash flow | -29.59M | 33.61M | 11.94M | 43.84M | 6.18M |
| Financing cash flow | 21.12M | 7.86M | 3.24M | 5.07M | 13.99M |
| Change in cash | -21.38M | 13.87M | -14.52M | 9.88M | -32.76M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 8-K — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | DEFA14A — Allogene Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | DEFA14A — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | 10-Q — Allogene Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | 144 — Allogene Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Yoshiyama Annie | View Filing | |
| edgar index | PRE 14A — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | 424B5 — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Allogene Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | 424B5 — Allogene Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | 144 — Allogene Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Beneski Benjamin Machinas | View Filing | |
| edgar index | 4 — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | 144 — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | 144 — Allogene Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Chang David D | View Filing | |
| form 4 | Form 4 — Chang David D | View Filing | |
| form 4 | Form 4 — Chang David D | View Filing | |
| form 4 | Form 4 — Chang David D | View Filing | |
| form 4 | Form 4 — Beneski Benjamin Machinas | View Filing | |
| edgar index | 8-K — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | 10-K — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | S-8 — Allogene Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 4 — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | 144 — Allogene Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Beneski Benjamin Machinas | View Filing | |
| edgar index | SCHEDULE 13G/A — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13D/A — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | 144 — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | 144 — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | 144 — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | 144 — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | 144 — Allogene Therapeutics, Inc. | View Filing | |
| edgar index | 144 — Allogene Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Belldegrun Arie | View Filing | |
| form 4 | Form 4 — Belldegrun Arie | View Filing | |
| form 4 | Form 4 — Belldegrun Arie | View Filing | |
| form 4 | Form 4 — Belldegrun Arie | View Filing | |
| form 4 | Form 4 — Belldegrun Arie | View Filing | |
| form 4 | Form 4 — Belldegrun Arie | View Filing | |
| form 4 | Form 4 — Belldegrun Arie | View Filing | |
| form 4 | Form 4 — Douglas Earl Martin | View Filing | |
| form 4 | Form 4 — Douglas Earl Martin | View Filing | |
| form 4 | Form 4 — Douglas Earl Martin | View Filing | |
| form 4 | Form 4 — Roberts Zachary | View Filing | |
| form 4 | Form 4 — Roberts Zachary | View Filing | |
| form 4 | Form 4 — Roberts Zachary | View Filing |